Objective To investigate the correlation between telomere length of peripheral white blood cells and the levels of advanced glycosylation end products,as well as bone mineral density in patients with type 2 diabetes mellitus,and to assess the impact of advanced glycosylation end product levels on telomere length.Methods From May 1,2023,to May 1,2024,174 patients with T2DM who underwent dual-energy X-ray BMD examination at the Department of Endocrinology,Zhengzhou Central Hospital,were selected.T2DM patients were divided into osteoporosis group,osteopenia group,and normal bone mass group based on the T-value in BMD.qPCR method was used to measure telomere length in peripheral blood leukocytes,and ELISA method was used to determine AGEs levels.General patient data were collected along with measurements for blood glucose,blood lipid levels,25-hydroxy-vitamin D,and other indicators.Bone mineral density was evaluated using dual-energy X-ray imaging while plasma CTX and PINP levels were measured via ELISA.SPSS 26.0 statistical software was utilized to analyze differences and correlations among all indicators.Results(1)The telomere length of OP group,osteopenia group and normal bone mass group was different,and the telomere length of the three groups increased successively.(2)In individuals with type 2 diabetes mellitus,telomere length exhibited a positive correlation with BMD and a negative correlation with CTX and PINP.Plasma AGEs level showed a negative correlation with BMD and a positive correlation with CTX and PINP,while telomere length demonstrated a negative correlation with AGEs level.(3)Telomere length was an independent factor of BMD,and AGEs level was an independent factor of BMD(P<0.05).Conclusion The reduction of telomere length and the increase of AGEs in patients with type 2 diabetes are related to the decrease of bone mineral density,and the reduction of telomere length is related to the increase of AGEs.Telomere length of peripheral leucocytes and plasma AGEs level can jointly evaluate the bone metabolism status of T2DM patients.

Depressive disorder is a mental illness characterized by poor mood and cognitive dysfunction caused by a range of complicated factors. Antidepressants have strong short-term efficacy in clinical application, yet with significant adverse effects and resistance in long-term use. Essential oils are small molecular compounds mainly composed of monoterpenes and sesquiterpenes, most of which are characterized by aromatic odors, easy permeability through the blood-brain barrier, and low toxic side effects. Volatile oil from traditional Chinese medicine can regulate neurotransmitter monoamine, hypothalamic-pituitary-adrenal axis, brain-derived neurotrophic factor, neuroinflammation and oxidative stress, and intestinal microbiota-gut-brain axis to exert an antidepressant effect through multiple pathways and targets. This review summarizes the main antidepressant chemical components of essential oil of traditional Chinese medicine, their pharmacological mechanisms and clinical application, aiming to provide some reference for further development and clinical application of essential oil of traditional Chinese medicine.

OBJECTIVE To evaluate the safety of fondaparinux in pregnancy and provide reference for its rational clinical application. METHODS A search was conducted in databases including CNKI， Wanfang， PubMed， Embase， and Elsevier （the search time was from the construction of the database to December 17， 2024） to collect case report literature on fondaparinux use during pregnancy. Patient demographic information， fondaparinux use during pregnancy， concomitant medications， clinical manifestations， and treatment details were extracted for descriptive statistical analysis. RESULTS A total of 17 case reports regarding the use of fondaparinux during pregnancy were collected， involving 42 patients from 11 countries and 47 pregnancy records. Among these， 20 cases involved the use of fondaparinux for the prevention of pregnancy-related venous thromboembolism （VTE）， while 27 cases were fondaparinux treatment due to related conditions. A total of 29 occurrences of the patients were treated with fondaparinux due to a （family） history of VTE. Nine occurrences of complicated pregnancies were reported， and 35 patients had records of comorbidities or relevant medical histories. The adverse events that occurred during pregnancy with the use of fondaparinux include postpartum hemorrhage （7 cases） and excessive anticoagulation caused by inappropriate dosage （1 case）. Among the 7 cases of postpartum hemorrhage， 3 cases had a blood loss of no less than 1 000 mL （including 2 cases with uterine atony）， 3 cases had a drug discontinuation time of ≤12 h. CONCLUSIONS Based on the existing literature， the safety of fondaparinux during pregnancy is generally manageable， with the main adverse event being postpartum hemorrhage. The dosage， interval between discontinuation，comorbidities/medical history， and concomitant medications of fondaparinux may be the main causes of its adverse events.